Gigoux, M., Zappasodi, R., Park, J., Bozkus, C. C., Mangarin, L., Redmond, D., … Merghoub, T. (2021). 772 MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms is countered by heteroclitic peptide cancer vaccination. In Regular and Young Investigator Award Abstracts (pp. A807–A807). BMJ Publishing Group Ltd. https://doi.org/10.1136/jitc-2021-sitc2021.772

Gigoux, Mathieu, Roberta Zappasodi, Joseph Park, Cansu Cimen Bozkus, Levi Mangarin, David Redmond, Svena Verma, et al. “772 MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms is countered by heteroclitic peptide cancer vaccination.” In Regular and Young Investigator Award Abstracts, A807–A807. BMJ Publishing Group Ltd, 2021. https://doi.org/10.1136/jitc-2021-sitc2021.772.

Gigoux M, Zappasodi R, Park J, Bozkus CC, Mangarin L, Redmond D, et al. 772 MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms is countered by heteroclitic peptide cancer vaccination. In: Regular and Young Investigator Award Abstracts. BMJ Publishing Group Ltd; 2021. p. A807–A807.

Gigoux, Mathieu, et al. “772 MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms is countered by heteroclitic peptide cancer vaccination.” Regular and Young Investigator Award Abstracts, BMJ Publishing Group Ltd, 2021, pp. A807–A807. Crossref, doi:10.1136/jitc-2021-sitc2021.772.

Gigoux M, Zappasodi R, Park J, Bozkus CC, Mangarin L, Redmond D, Verma S, Schad S, George M, Venkatesh D, Ghosh A, Molvi Z, Kamaz B, Marneth A, Duke W, Leventhal M, Jan M, Ho V, Hobbs G, Knudsen T, Skov V, Kjær L, Larsen T, Hansen D, Lindsley R, Hasselbalch H, Grauslund J, Andersen M, Holmstrom M, Chan T, Rampal R, Abdel-Wahab O, Bhardwaj N, Mullally A, Wolchok J, Merghoub T. 772 MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms is countered by heteroclitic peptide cancer vaccination. Regular and Young Investigator Award Abstracts. BMJ Publishing Group Ltd; 2021. p. A807–A807.